ERBB2 and carcinoma: The secondary objective was to analyze the same parameters for patients with the ASCO/CAP group 4 carcinomas, a subcategory of the H2L carcinomas for which the available data, and especially molecular data, remain particularly scarce, and compare them to the characteristics of the other HER2 categories.